Comparative Pharmacology
Head-to-head clinical analysis: NEOSAR versus OXALIPLATIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NEOSAR versus OXALIPLATIN.
NEOSAR vs OXALIPLATIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Alkylating agent that inhibits DNA replication and transcription by cross-linking DNA strands, leading to cell cycle arrest and apoptosis.
Oxaliplatin is a platinum-based alkylating agent that forms inter- and intrastrand DNA crosslinks, inhibiting DNA replication and transcription, leading to cell death.
Cyclophosphamide 500-1500 mg/m² IV every 2-4 weeks; oral 50-200 mg daily.
85 mg/m² intravenously over 2 hours every 2 weeks in combination with 5-fluorouracil and leucovorin (FOLFOX regimen).
None Documented
None Documented
Terminal elimination half-life: 3-5 hours; prolonged in hepatic impairment (up to 12 hours).
Clinical Note
moderateOxaliplatin + Digoxin
"Oxaliplatin may decrease the cardiotoxic activities of Digoxin."
Clinical Note
moderateOxaliplatin + Digitoxin
"Oxaliplatin may decrease the cardiotoxic activities of Digitoxin."
Clinical Note
moderateOxaliplatin + Deslanoside
"Oxaliplatin may decrease the cardiotoxic activities of Deslanoside."
Clinical Note
moderateOxaliplatin + Acetyldigitoxin
"Oxaliplatin may decrease the cardiotoxic activities of Acetyldigitoxin."
Terminal elimination half-life is approximately 40-50 hours for ultrafilterable platinum (active species) and 240-500 hours for total platinum (bound to plasma proteins and erythrocytes). The prolonged half-life reflects slow release from tissue binding.
Renal: 30-60% unchanged; biliary/fecal: 10-20% as metabolites.
Renal excretion accounts for approximately 50% of the administered platinum, with the remainder eliminated via biliary/fecal routes. Platinum accumulates in erythrocytes and is slowly cleared.
Category C
Category D/X
Alkylating Agent
Alkylating Agent